Poor outcome of #SARS-CoV-2 infection in patients with severe #asthma on biologic therapy
It is unclear whether asthma and asthma medications increase or decrease the risk of severe COVID-19, and this is particularly true for patients with severe asthma receiving biologics. Objectives The aim of this study was to assess incidence and disease course of COVID-19 in patients with severe asthma on biologic therapy (omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab), as compared with COVID-19 data from the general Dutch … Continue reading Poor outcome of #SARS-CoV-2 infection in patients with severe #asthma on biologic therapy